ACRIN Fall Meeting 2009 ACRIN Adverse Event Reporting Manual Revisions Presented by: Cornelia Tsikos, BS, MS.

Slides:



Advertisements
Similar presentations
HL7 Working Group Meeting Orlando, Florida 14 January
Advertisements

Glenna Gabrielli, Senior Research Associate
Associate Chief, Senior Investigator
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.
Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:
Common Terminology Criteria for Adverse Events (CTCAE) v.4: Updating a Cancer Research Standard Ann Setser 1, Ranjana Srivastava 2, Lawrence Wright 1,
National Cancer Institute Cancer Therapy Evaluation Program (CTEP) presents: How to Obtain Protected Health Information (PHI) from an Outside Healthcare.
THE UW HEALTH SCIENCES IRB S OVERVIEW PRACTICAL REGULATORY ISSUES IN HUMAN SUBJECTS RESEARCH.
Multi-Institutional Facilitated IRB Review Philip A. Cola, MA Vice President, Research and Technology University Hospitals Case Medical Center Third Annual.
Research Protocol ACRIN 6678 Learning About PET/CT Scans: Can PET/CT scans provide helpful information for the treatment of non-small cell lung cancer?
Welcome to Sterling IRB Our Total Commitment. Your Total Confidence
 The National Cancer Institute (NCI) is:  The largest of the Institutes that constitute the National Institutes of Health  The largest sponsor of research.
IRB-Investigator/ Research Coordinator Mtg. “What You Can Do to Facilitate an Efficient IRB Review” January 13, 2004 George Gasparis.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
FDA Final Rule & Revised CTEP Guidelines for Expedited Reporting of Adverse Events S. Percy Ivy, MD Associate Chief, Senior Investigator Investigational.
Overview of Good Clinical Practices (GCPs)
Lisa Denney, MPH HRPP Assistant Director Melanie Mace, MA HRPP Education and Training Coordinator Bill Woods, PhD CAPS Policy and Ethics Core November.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Revised Audit Manual – Fall Meeting 2009 September 30, 2009 REVISED AUDIT MANUAL Chris Steward, ACRIN Quality Control Auditor.
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
RESCUE 4701 Adverse Event Reporting October 16, 2010 Maria Oh, Director Protocol Development & Regulatory Compliance.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.
Imaging Core Laboratory Fall Meeting, 2011 Imaging Challenges for ACRIN sites Compliance and set-up Anthony M. Levering Assistant Director, Core lab.
FDA’s Draft LDT Framework & Personalized Medicine Update
Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)
CRIX: toward a secure, standards-based, clinical research information exchange.
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
Consent for Research Study A study using 18 F-Fluoride for prostate cancer patients currently enrolled in Dr. Febbo’s “Genomic Guided Therapy” study A.
NFBIO: Update on NCI Imaging Activities Daniel C. Sullivan, M.D. Cancer Imaging Program, DCTD, NCI.
Inclusion of Women in Clinical Trials & Drug Development Regulatory Perspective Ameeta Parekh, Ph.D. R&D Director Office of Women’s Health Food & Drug.
Division of AIDS Data Interchange DAIDS Adverse Experience Reporting System (DAERS) New User Introductory Training Teleconferencing Details: US Toll Free:
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
FDA Regulatory and Compliance Symposium
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
How to Start An Industry Sponsored Clinical Trial
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
1 SAE Centralized Report and Review Process April 2012.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
ClinicalTrials.gov Requirements
Introduction to the Human Research Protections Office (HRPO)
MAINTAINING THE INVESTIGATOR’S SITE FILE
Clinicaltrials.gov Update
Investigator of Record – Definition
Office of Sponsored Projects
Alyssa Speier, MS, CIP November 13, 2013
ClinicalTrials.gov: An introduction
IRB – Human subjects research incoming staff orientation 2017
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Learning About PET/CT Scans:
Overview - Introduction
Associate Chief, Senior Investigator
Elements of an Organized Regulatory Binder
FDA Medical Device Approval Pathways
Investigator of Record – Definition
Investigator of Record – Definition
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Human Gene Therapy Institutional Review Procedures
Changes to the Common Rule and Single IRB (sIRB)
Research with Human Subjects
Presentation transcript:

ACRIN Fall Meeting 2009 ACRIN Adverse Event Reporting Manual Revisions Presented by: Cornelia Tsikos, BS, MS

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Overview Revisions to the Adverse Event Reporting Manual Introduction of the Regulatory Resources Webpage

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Alphabetized list and addition of... Baseline Adverse Event C3D CAEPR Comprehensive Adverse Events & Potential Risk List Expedited Reporting Routine Reporting Section 1: AE Terminology & Definitions

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Section 2: Adverse Event Reporting Six Categories of ACRIN Studies 1.Diagnostic 2.Screening 3.Interventional 4.Investigational Agents 5.Investigational Device 6.Collaborative

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Section 3: Expedited AE Reporting Reflects current practices Compliance with federal regulatory requirements Protocol-specific AE reporting requirements will supersede the guidelines of the manual.

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Electronic Adverse Event Reporting System (AdEERS) 24 hour electronic reporting instructions Submission through web application System unavailable Training Assistance Section 3: Expedited AE Reporting

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 New Sections in AE Reporting Manual Section 4: Reporting Requirements for Diagnostic Studies Section 5: Reporting Requirements for Screening Studies Section 6: Reporting Requirements for Interventional Studies

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 New Sections in AE Reporting Manual Section 7: Reporting Requirements for Studies Using Investigational Agents Section 8: Reporting Requirements for Studies Using Investigational Devices Section 9: Reporting Requirements for Collaborative Clinical Studies

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Section 10: Additional Resources ACRIN’s Protocol Development & Regulatory Resources –Updated AE Reporting Manual AdEERS Resources National Cancer Institute (NCI) Resources –NCI Cancer Imaging Program (CIP) –NCI Cancer Therapy Evaluation Program (CTEP) AdEERS Reporting U.S. Food and Drug Administration (FDA)

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Section 11: Appendix NCI-CIP AE Reporting Guidance Documents: Appendix 1: Phase 1 through Early Phase 2 CIP-IND Imaging Agent Trials Appendix 2: Late Phase 2 through Phase 3 CIP-IND Imaging Agent Trials Appendix 3: Commercial (Non-IND) Imaging Agent Trials

ACRIN Fall Meeting 2009

January 31, 2008 ACRIN: Principles & Practice of Clinical ResearchACRIN Fall Meeting 2009 Reminder Always Available for Questions ACRIN Adverse Event Coordinator –(215) –Ask for an ACRIN AE Coordinator Assistance Completing AdEERS Report AdEERS MD Line (medical questions) –(301) AdEERS Technical Help –(888)

ACRIN Fall Meeting 2009 Contact Information Cornelia (Lia) Tsikos, BS, MS ACRIN AE Coordinator & ACRIN Research Associate Phone: Fax :